APREA THERAPEUTICS INC (APRE) Stock Analyst Ratings
USA - NASDAQ:APRE - US03836J2015 - Common Stock
1.191 USD
+0 (+0.08%)
ChartMill assigns a Buy % Consensus number of 85% to APRE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.71. This target is 799.24% above the current price.
APRE was analyzed by 8 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about APRE.
In the previous month the buy percentage consensus was at a similar level.
APRE was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-10 | Maxim Group | Initiate | Buy |
| 2022-07-08 | Wedbush | Initiate | Outperform |
| 2021-08-20 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-08-16 | Berenberg | Downgrade | Buy -> Hold |
| 2021-08-16 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-08-13 | RBC Capital | Maintains | Sector Perform |
| 2021-08-13 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-03-17 | RBC Capital | Maintains | Sector Perform |
APREA THERAPEUTICS INC / APRE FAQ
What do analysts expect the price target to be for APREA THERAPEUTICS INC (APRE)?
8 analysts have analysed APRE and the average price target is 10.71 USD. This implies a price increase of 799.24% is expected in the next year compared to the current price of 1.191.
How do analysts rate APREA THERAPEUTICS INC (APRE)?
The consensus rating for APREA THERAPEUTICS INC (APRE) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.